KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to -$103.2 million.

  • Sarepta Therapeutics' Change in Accured Expenses fell 622302.67% to -$103.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.1 million, marking a year-over-year decrease of 14446.9%. This contributed to the annual value of $110.6 million for FY2024, which is 32070.21% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Change in Accured Expenses of -$103.2 million as of Q3 2025, which was down 622302.67% from -$24.5 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Change in Accured Expenses peaked at $124.2 million during Q4 2024, and registered a low of -$103.2 million during Q3 2025.
  • Over the past 5 years, Sarepta Therapeutics' median Change in Accured Expenses value was -$5.0 million (recorded in 2022), while the average stood at $4.5 million.
  • In the last 5 years, Sarepta Therapeutics' Change in Accured Expenses skyrocketed by 39697.26% in 2024 and then plummeted by 622302.67% in 2025.
  • Sarepta Therapeutics' Change in Accured Expenses (Quarter) stood at $69.8 million in 2021, then crashed by 81.55% to $12.9 million in 2022, then soared by 374.36% to $61.1 million in 2023, then surged by 103.34% to $124.2 million in 2024, then crashed by 183.06% to -$103.2 million in 2025.
  • Its Change in Accured Expenses was -$103.2 million in Q3 2025, compared to -$24.5 million in Q2 2025 and -$17.7 million in Q1 2025.